Torasemid Zentiva 2.5 mg
Long-acting loop diuretic (torasemide) for essential hypertension
Torasemid Zentiva 2.5 mg is a prescription-only tablet containing torasemide, a long-acting loop diuretic that increases urinary excretion of sodium, chloride, and water. At this low strength, it is used primarily for the treatment of essential hypertension (high blood pressure), where its gentle and sustained diuretic effect produces predictable blood pressure lowering with less risk of excessive fluid loss than higher-dose formulations. Torasemide offers more predictable absorption and a longer duration of action than furosemide, allowing once-daily dosing in most patients.
Quick Facts
Key Takeaways
- Torasemid Zentiva 2.5 mg contains torasemide, a loop diuretic primarily indicated for the treatment of essential hypertension, typically as part of combination therapy or when thiazides are not tolerated.
- Torasemide has higher and more predictable oral bioavailability (80–90%) than furosemide and a longer duration of action (6–8 hours), supporting reliable once-daily dosing.
- Regular monitoring of potassium, sodium, magnesium, kidney function, blood glucose, and uric acid is essential, particularly during the first weeks of treatment and in elderly patients.
- The tablet should be taken in the morning, swallowed whole with water, and can be taken with or without food. Do not discontinue abruptly without medical advice.
- Torasemide is contraindicated in patients with severe dehydration, anuria, hepatic coma, severe electrolyte imbalance, and during breastfeeding. It is structurally related to sulfonamides and should be avoided in patients with documented sulfonamide hypersensitivity.
What Is Torasemid Zentiva and What Is It Used For?
Quick Answer: Torasemid Zentiva 2.5 mg is a generic prescription tablet containing torasemide, a loop diuretic that lowers blood pressure by helping the kidneys remove excess sodium and water. At the 2.5 mg strength, it is primarily used for essential hypertension, either alone or in combination with other antihypertensive medications.
Torasemid Zentiva is a branded generic formulation of torasemide (also spelled torsemide) manufactured by Zentiva, a European pharmaceutical company that produces high-quality generic medicines. Torasemide belongs to the class of loop diuretics, a group of potent "water tablets" that act on the loop of Henle inside the kidney to promote the excretion of water and electrolytes. It was first introduced to clinical practice in the 1990s and has since become a widely used alternative to furosemide in both hypertension and heart failure management.
The active substance torasemide works by inhibiting the sodium-potassium-chloride cotransporter (NKCC2) in the thick ascending limb of the loop of Henle. By blocking this transporter, torasemide prevents sodium, chloride, and water from being reabsorbed into the bloodstream. The kidneys therefore excrete more urine, which reduces the overall volume of fluid in the circulation and ultimately lowers blood pressure. A distinctive feature of torasemide is its additional anti-aldosterone effect: it partially blocks the mineralocorticoid receptor, which may contribute to a more balanced potassium profile and, in heart failure, beneficial anti-fibrotic effects on the heart.
Torasemid Zentiva 2.5 mg is the lowest available strength of torasemide and is the formulation most appropriate for managing high blood pressure. Typical clinical indications include:
- Essential hypertension: The primary indication at the 2.5 mg strength. Torasemide is used either as monotherapy in mild hypertension or, more commonly, in combination with other antihypertensives (such as ACE inhibitors, angiotensin receptor blockers, calcium channel blockers or beta-blockers) when blood pressure targets are not met with a single agent. It is particularly useful in patients with salt-sensitive hypertension, mild renal impairment, or when thiazide diuretics are not tolerated or effective.
- Adjunct in heart failure (at higher strengths): While the 2.5 mg tablet is generally too low for heart failure, patients may be titrated upwards to 5, 10, or 20 mg of torasemide once-daily for chronic heart failure with signs of congestion. Some clinical trials, including the TRANSFORM-HF study, have compared torasemide with furosemide in heart failure outcomes.
- Oedema due to hepatic or renal disease (at higher strengths): In patients with ascites, peripheral oedema, or nephrotic syndrome, torasemide can be used to mobilise excess fluid. These indications usually require doses above 2.5 mg.
Compared with other loop diuretics, torasemide has several pharmacokinetic advantages. Oral absorption is rapid, almost complete, and minimally affected by food or heart failure-related gut oedema, giving it a bioavailability of approximately 80–90%. This is particularly valuable in patients with decompensated heart failure where gastrointestinal absorption of furosemide can be erratic. Torasemide is primarily metabolised in the liver by the CYP2C9 enzyme, so its clearance is less dependent on kidney function than furosemide. Its elimination half-life of approximately 3 to 4 hours is notably longer, producing a smoother and more sustained diuretic effect over 6 to 8 hours, with less of the abrupt "post-diuretic sodium retention" seen with shorter-acting loops.
Because Torasemid Zentiva is a generic product, it is therapeutically equivalent to the originator torasemide and to other generic brands containing the same active ingredient at the same strength. Your pharmacist may substitute another torasemide product with identical strength unless your prescriber has indicated that substitution should not take place.
What Should You Know Before Taking Torasemid Zentiva?
Quick Answer: Torasemid Zentiva should not be used if you are allergic to torasemide or sulfonamide-derived drugs, severely dehydrated, have very low potassium or sodium, cannot produce urine (anuria), or are breastfeeding. Use with caution if you have diabetes, gout, liver disease, urinary outflow obstruction, or low blood pressure, and whenever you take other medicines that affect kidney function or electrolytes.
Contraindications
Torasemid Zentiva must not be used in the following situations. Your doctor will review your medical history before prescribing to confirm that none of these apply to you:
- You are allergic (hypersensitive) to torasemide, to sulfonamide-derived medicines (such as certain antibiotics, sulfonylurea antidiabetics, or other loop/thiazide diuretics), or to any of the excipients in the tablet
- You have severe low blood pressure (hypotension), severe dehydration, or significantly reduced circulating blood volume
- You have anuria (complete absence of urine production) or acute kidney failure with anuria that does not respond to diuretic therapy
- You have severe hypokalemia (very low potassium) or severe hyponatremia (very low sodium)
- You are in hepatic coma or pre-coma (hepatic encephalopathy)
- You are breastfeeding – torasemide is believed to pass into breast milk and may suppress lactation
- You have a history of diuretic-induced severe gout or renal disease where the risk outweighs the benefit
Warnings and Precautions
Inform your doctor before starting Torasemid Zentiva if any of the following apply. These conditions do not necessarily prevent treatment but may require dose adjustment, additional monitoring, or an alternative choice of antihypertensive:
- Low blood pressure (hypotension) and circulatory disorders: Torasemide can reduce blood pressure further, especially when treatment is initiated or when doses are increased. Patients with pre-existing low blood pressure, arterial stenoses (e.g. carotid or coronary), or orthostatic hypotension are at higher risk of symptomatic dizziness, fainting, falls, and — in rare cases — ischaemic events.
- Diabetes mellitus and metabolic syndrome: Like other loop and thiazide diuretics, torasemide can impair glucose tolerance and raise blood sugar. Patients with diabetes or pre-diabetes may need closer monitoring of HbA1c and adjustment of their antidiabetic therapy.
- Gout or hyperuricaemia: Torasemide reduces urate excretion and may raise serum uric acid, which can trigger gout attacks in susceptible patients. Consider alternative diuretics or prophylactic urate-lowering therapy where appropriate.
- Urinary outflow obstruction: In men with prostate enlargement and in any patient with suspected urinary obstruction, adequate urine flow must be confirmed before starting treatment. A sudden diuretic response in an obstructed urinary tract can precipitate acute urinary retention.
- Liver disease: In patients with hepatic cirrhosis, electrolyte and acid-base disturbances caused by diuretics can precipitate or worsen hepatic encephalopathy. Dose titration should be slow and under close supervision.
- Kidney disease: Torasemide is effective in mild to moderate renal impairment and is often preferred over thiazides when eGFR falls below 30 mL/min/1.73m². However, aggressive diuresis in advanced chronic kidney disease can worsen kidney function; fluid balance, creatinine, and electrolytes must be monitored.
- Electrolyte imbalance and dehydration: Pre-existing low potassium, sodium, magnesium, or calcium should be corrected before starting treatment. Additional losses from vomiting, diarrhoea, heavy sweating, or fever can rapidly unmask or worsen imbalances during diuretic therapy.
- Elderly patients: Older adults are more sensitive to the blood-pressure lowering and volume-depleting effects of loop diuretics. A lower starting dose (often 2.5 mg) and slower titration, together with more frequent laboratory monitoring, are recommended.
- Hearing impairment: Although less ototoxic than furosemide, high doses of torasemide — particularly in combination with aminoglycoside antibiotics or cisplatin — can potentially cause reversible or, rarely, irreversible hearing impairment and tinnitus.
During torasemide therapy, your doctor will regularly check your serum potassium, sodium, magnesium, calcium, creatinine, urea, glucose, uric acid, and lipid profile. Home blood-pressure monitoring (including standing blood pressure) is encouraged. Report any signs of excessive fluid loss – persistent thirst, dry mouth, weakness, confusion, muscle cramps, rapid weight loss, or dark concentrated urine – to your doctor promptly.
Pregnancy and Breastfeeding
Pregnancy. There is limited clinical data on the use of torasemide in pregnant women. Torasemide crosses the placental barrier, and animal studies have shown dose-dependent foetal toxicity. Diuretics are generally not recommended for the treatment of gestational hypertension or pre-eclampsia because they can further reduce placental perfusion. Torasemid Zentiva should therefore only be used during pregnancy when strictly necessary and when safer alternatives have been considered, and always under specialist supervision.
Breastfeeding. It is not known to what extent torasemide passes into human breast milk, but related loop diuretics do. Torasemide may also suppress lactation. For these reasons, breastfeeding is contraindicated during treatment with Torasemid Zentiva. If ongoing diuretic therapy is essential, you should discuss with your doctor whether to stop breastfeeding or to switch to an alternative medication.
Fertility. There are no reliable data to suggest that torasemide at therapeutic doses affects male or female fertility.
Driving and Operating Machinery
Torasemid Zentiva can cause dizziness, headache, fatigue, visual disturbances, and symptomatic drops in blood pressure, especially at the start of treatment, when doses are changed, or when it is combined with alcohol or other antihypertensive agents. These effects can impair reaction times and should be assessed individually before driving, cycling, or operating machinery.
How Does Torasemid Zentiva Interact with Other Drugs?
Quick Answer: Torasemide interacts with many commonly used drugs. The most clinically significant interactions are with aminoglycoside antibiotics and cisplatin (ear and kidney toxicity), digoxin (toxicity due to low potassium), lithium (lithium toxicity), NSAIDs (reduced diuretic effect and kidney damage), ACE inhibitors/ARBs (first-dose hypotension and acute kidney injury), and cholestyramine (reduced torasemide absorption).
Because torasemide alters renal handling of sodium, potassium, magnesium, and uric acid, and because it lowers blood pressure and circulating volume, it can influence the efficacy and safety of many medications. Always provide your doctor and pharmacist with a complete list of your prescription medicines, over-the-counter products, herbal remedies, and supplements – including items such as ibuprofen, licorice confectionery, laxatives, and St John's Wort.
Major Interactions – Avoid or Use with Extreme Caution
| Drug / Class | Mechanism | Clinical Consequence |
|---|---|---|
| Aminoglycosides (gentamicin, tobramycin, amikacin) | Additive ototoxicity and nephrotoxicity | Increased risk of hearing loss and kidney damage. Avoid combination when possible; if unavoidable, use lowest effective doses and monitor renal and auditory function. |
| Cisplatin and other platinum chemotherapies | Additive nephrotoxicity and ototoxicity | Substantially increased risk of acute kidney injury and permanent hearing loss. Close monitoring required during oncology treatment. |
| Other ototoxic drugs (e.g. ethacrynic acid) | Additive damage to cochlear hair cells | High risk of permanent deafness. Combination should be avoided. |
| Lithium | Reduced renal lithium clearance | Elevated serum lithium levels with risk of neurotoxicity (tremor, confusion) and cardiotoxicity. Check lithium levels before and after initiating torasemide. |
| Risperidone and other antipsychotics in elderly patients with dementia | Combined cardiovascular and dehydration risk | Increased mortality observed with concurrent diuretic and antipsychotic use in dementia-related psychosis. Reassess indication carefully. |
Moderate Interactions – May Require Dose Adjustment or Monitoring
| Drug / Class | Mechanism | Clinical Consequence |
|---|---|---|
| ACE inhibitors / ARBs (enalapril, ramipril, losartan, valsartan) | Additive hypotension; risk of acute kidney injury from combined RAS inhibition and volume depletion | First-dose hypotension can be severe. Consider withholding or lowering torasemide before starting an ACE inhibitor/ARB, and monitor renal function and potassium. |
| Digoxin | Hypokalemia and hypomagnesemia potentiate digoxin toxicity | Increased risk of cardiac arrhythmias. Maintain serum potassium > 4.0 mmol/L and monitor for nausea, visual disturbances, bradycardia. |
| NSAIDs (ibuprofen, naproxen, diclofenac) and COX-2 inhibitors | Inhibition of renal prostaglandin synthesis; additive nephrotoxicity | Reduced diuretic and antihypertensive effect; risk of acute kidney injury, especially in combination with RAS inhibitors ("triple whammy"). Avoid prolonged NSAID use. |
| Probenecid | Competitive inhibition of torasemide secretion into renal tubules | Reduced diuretic response; dose adjustment may be needed. |
| Cholestyramine, colestipol | Binding in the gut reduces torasemide absorption | Markedly reduced diuretic effect. Take torasemide at least 2–4 hours apart from bile acid sequestrants. |
| Corticosteroids and ACTH | Additive potassium loss and sodium retention | Increased risk of hypokalemia and reduced antihypertensive effect; monitor potassium and blood pressure. |
| Antidiabetic drugs (insulin, sulfonylureas) | Torasemide can impair glucose tolerance | Higher blood glucose readings; antidiabetic dose may need adjustment. |
| Other antihypertensives (beta-blockers, calcium channel blockers) | Additive blood pressure lowering | Desirable in hypertension management, but requires careful titration to avoid symptomatic hypotension. |
| Salicylates (high-dose aspirin) | Reduced uric acid and salicylate excretion | Increased risk of salicylate toxicity in patients on high-dose aspirin for inflammatory conditions. |
| Laxative abuse / Licorice (in large amounts) | Additive potassium loss | Severe hypokalemia. Avoid chronic laxative use and limit licorice intake. |
| Curare-type muscle relaxants | Potentiation by electrolyte disturbances | Prolonged neuromuscular blockade during anaesthesia. Inform your anaesthetist that you take torasemide. |
Torasemide is metabolised by the CYP2C9 hepatic enzyme. Potent CYP2C9 inhibitors (such as fluconazole or amiodarone) may increase torasemide exposure, while inducers (such as rifampicin) may reduce it. Dose adjustments are rarely needed, but additional monitoring is prudent when starting or stopping such medications.
What Is the Correct Dosage of Torasemid Zentiva?
Quick Answer: For essential hypertension, the typical adult dose of torasemide is 2.5 mg once daily in the morning, with or without food, increased to 5 mg if blood pressure control is inadequate after 8–12 weeks. Elderly patients usually start at 2.5 mg. Torasemid Zentiva is not recommended for children. Never take a double dose to make up for a missed one.
Torasemide dosage is individualised according to the clinical indication, response, kidney and liver function, and the combination of other antihypertensive medicines. The principle is to use the lowest effective dose that provides stable blood-pressure control while avoiding dehydration and electrolyte imbalance. The information below is based on international prescribing guidance – always follow the precise instructions given by your doctor and pharmacist.
Adults – Essential Hypertension
Recommended adult dose
Start with 2.5 mg torasemide once daily, taken in the morning. If blood pressure is not adequately controlled after 8–12 weeks, the dose may be increased to 5 mg once daily. Doses higher than 5 mg/day do not generally provide additional blood pressure reduction and are typically reserved for oedema-related indications using higher-strength tablets.
| Indication | Starting Dose | Typical Range | Maximum Daily Dose |
|---|---|---|---|
| Essential hypertension | 2.5 mg once daily | 2.5–5 mg once daily | 5 mg (hypertension indication) |
| Oedema – chronic heart failure | 5–10 mg once daily | 10–20 mg once daily | 200 mg (specialist use) |
| Oedema – hepatic cirrhosis | 5–10 mg once daily | 10–40 mg once daily | 40 mg |
| Oedema – chronic kidney disease | 20 mg once daily | 20–100 mg once daily | 200 mg |
How to take the tablet. Torasemid Zentiva 2.5 mg tablets should be swallowed whole with a glass of water in the morning, with or without food. If a second dose is ever prescribed, it should be taken no later than early afternoon to reduce nocturia (nighttime urination). Do not crush or chew the tablet unless your pharmacist has specifically advised this is acceptable for your product.
Consistency matters. Take your tablet at roughly the same time each day. Blood pressure and fluid balance improve gradually, and the full antihypertensive effect is usually reached after 8 to 12 weeks of continuous treatment. Do not stop taking the medication because you feel better – hypertension often causes no symptoms even when it is causing organ damage.
Children and Adolescents
The safety and efficacy of torasemide in children and adolescents below 18 years have not been established. Torasemid Zentiva is therefore not recommended for paediatric use. Alternative diuretics with established paediatric data, such as furosemide or spironolactone, are typically preferred under the supervision of a paediatric specialist.
Elderly Patients
No routine dose adjustment is required in elderly patients, but older adults are more susceptible to volume depletion, electrolyte disturbances, hypotension, falls, and acute kidney injury. The lowest available dose – 2.5 mg – is usually an appropriate starting point, with slow titration and more frequent laboratory monitoring. Standing and lying blood pressure should be measured to detect orthostatic hypotension, particularly when torasemide is combined with other antihypertensive agents.
Patients with Hepatic or Renal Impairment
In mild-to-moderate renal impairment, torasemide typically remains effective at standard doses because its clearance is predominantly hepatic. In severe renal impairment, higher doses may be needed to achieve an adequate response, always under specialist supervision. In hepatic impairment, torasemide plasma levels may rise because of reduced CYP2C9-mediated metabolism; careful dose titration and monitoring of electrolytes and mental status are required, particularly in cirrhosis where hepatic encephalopathy can be triggered.
Missed Dose
If you forget to take a dose, take it as soon as you remember – unless it is already late in the day, in which case skip the missed dose and take your next dose at the usual morning time. Do not take a double dose to make up for the one you missed; this can lead to excessive fluid loss, low blood pressure, and dangerous electrolyte changes.
Stopping Treatment
Do not stop taking Torasemid Zentiva suddenly without consulting your doctor, as this can result in rebound increases in blood pressure or reaccumulation of fluid. If treatment needs to be discontinued, your doctor will usually taper the dose or replace it with an alternative antihypertensive.
Overdose
An overdose of torasemide can cause severe dehydration, dangerous electrolyte disturbances (especially low potassium), marked hypotension with risk of circulatory collapse, confusion, and acute kidney failure. If you suspect an overdose, contact your local emergency number or poison control centre immediately. Treatment is supportive and focuses on fluid and electrolyte replacement, careful blood pressure correction, and monitoring of renal function. Haemodialysis does not significantly remove torasemide.
What Are the Side Effects of Torasemid Zentiva?
Quick Answer: The most common side effects are dose-related consequences of the diuretic action: electrolyte imbalances, dehydration, elevated uric acid and glucose, raised blood lipids, and increased urination. Less common effects include headache, dizziness, gastrointestinal upset, and skin reactions. Rare but serious effects include severe allergic reactions, blood cell disorders, pancreatitis, and hearing disturbances.
All medicines can cause side effects, though not everyone experiences them. The frequency and severity of torasemide's adverse effects depend on the dose, duration of treatment, renal and hepatic function, and concurrent medications. Most adverse effects are predictable consequences of diuresis and are managed by dose adjustment, electrolyte replacement, and careful monitoring. The frequency categories below follow the standardised European Medicines Agency (EMA) classification.
Very Common (affects more than 1 in 10 people)
Very frequent – often detected through routine laboratory testing
- Electrolyte disturbances: low potassium (hypokalaemia), low sodium (hyponatraemia), low chloride and magnesium – may produce fatigue, muscle cramps, palpitations or weakness
- Metabolic alkalosis (raised blood pH)
- Increased urination (polyuria), particularly in the hours after taking the tablet
- Headache
Common (affects 1 in 10 to 1 in 100 people)
Regularly observed in clinical practice
- Dizziness and light-headedness, particularly on standing
- Fatigue and general weakness
- Nausea, vomiting, abdominal discomfort, diarrhoea or constipation
- Dry mouth and increased thirst
- Elevated blood uric acid (hyperuricaemia) – may trigger gout in predisposed patients
- Increased blood glucose and worsening glucose tolerance
- Raised blood lipids (triglycerides and cholesterol)
- Muscle cramps, especially overnight
- Mild elevations of liver enzymes (ALT, AST, gamma-GT)
Uncommon (affects 1 in 100 to 1 in 1,000 people)
Less frequent reactions
- Confusion, paraesthesia (tingling, numbness), mood disturbance
- Visual disturbances, tinnitus (ringing in the ears)
- Reversible hearing impairment, particularly at high doses or with concurrent ototoxic drugs
- Symptomatic hypotension with syncope (fainting)
- Skin reactions: rash, pruritus (itch), urticaria (hives), photosensitivity
- Gout attacks in patients with predisposition
- Erectile dysfunction
Rare (affects 1 in 1,000 to 1 in 10,000 people)
Rare adverse reactions
- Thrombocytopenia (low platelets) – increased bruising or bleeding
- Leukopenia (low white blood cell count) – increased infection risk
- Acute pancreatitis – severe upper abdominal pain, vomiting
- Severe hypersensitivity reactions including angio-oedema
- Significant acute kidney injury
- Thrombosis or embolism due to haemoconcentration, especially in the elderly
Very Rare (affects fewer than 1 in 10,000 people)
Very rare but clinically significant reactions
- Anaemia, agranulocytosis, aplastic anaemia
- Severe skin reactions: Stevens-Johnson syndrome, toxic epidermal necrolysis, acute generalised exanthematous pustulosis
- Cholestatic hepatitis or fulminant hepatic failure
- Irreversible hearing loss
Frequency Not Known
Reported in post-marketing surveillance; frequency cannot be estimated
- Worsening of systemic lupus erythematosus (SLE)
- Interstitial nephritis
- Hepatic encephalopathy in patients with liver disease
- Pseudo-Bartter syndrome with chronic high-dose use
- Calcium and phosphate imbalance, potential impact on bone health with long-term use
- Signs of severe allergic reaction: facial, lip or tongue swelling, difficulty breathing, widespread rash, collapse – call your local emergency number
- Severe dehydration or very low blood pressure: dizziness on standing, fainting, confusion, markedly reduced urine output
- Unexplained fever, sore throat, mouth ulcers, or bruising – may indicate bone marrow suppression and requires urgent blood tests
- Severe upper abdominal pain with vomiting – possible pancreatitis
- Sudden hearing changes or new tinnitus, especially at higher doses or with other ototoxic drugs
- Severe or spreading skin reaction, blistering or mucosal involvement – stop the tablet and seek urgent care
You can help regulators monitor the safety of Torasemid Zentiva and other medicines by reporting any suspected side effects to your national pharmacovigilance system (for example the MHRA Yellow Card Scheme, EMA EudraVigilance, or FDA MedWatch). Reporting helps build a more complete safety picture over time.
How Should You Store Torasemid Zentiva?
Quick Answer: Store Torasemid Zentiva 2.5 mg tablets below 25 °C in the original blister and outer carton, protected from moisture and light. Keep out of sight and reach of children. Do not use the tablets after the expiry date printed on the pack, and return any unused medication to your pharmacy for safe disposal.
Proper storage preserves the chemical stability of torasemide and ensures that the tablets remain safe and effective until the stated expiry date. Although the exact storage conditions may vary slightly between countries and manufacturers, the following general guidance applies:
- Temperature: Store below 25 °C (77 °F). Do not refrigerate or freeze. Avoid leaving the pack in direct sunlight, hot cars, or on windowsills.
- Humidity: Keep tablets in the original blister inside the outer carton to protect them from moisture. Do not store the medicine in the bathroom or kitchen, where humidity can be high.
- Light protection: The outer carton provides protection from light. Only press out the tablet immediately before taking it.
- Child safety: Keep Torasemid Zentiva out of the sight and reach of children. Even small quantities of diuretics can be dangerous if swallowed by a child.
- Expiry date: Do not use Torasemid Zentiva after the expiry date (EXP) printed on the carton and blister. The expiry date refers to the last day of the stated month.
- Inspection: Before taking, check that the tablet is intact and has its normal appearance. If tablets are crumbled, discoloured, or visibly damaged, do not use them.
- Disposal: Do not dispose of medications via wastewater or household waste. Return unused or expired medication to your pharmacy for safe disposal – this protects water systems and prevents accidental exposure.
If you are travelling, keep your torasemide in its original packaging and, where possible, carry a copy of your prescription or a letter from your doctor, particularly on international journeys. Loop diuretics are generally permitted through airport security, but long-haul travel can worsen dehydration risk – discuss fluid management with your doctor before longer trips.
What Does Torasemid Zentiva Contain?
Quick Answer: Each Torasemid Zentiva tablet contains 2.5 mg of the active substance torasemide, together with pharmaceutical excipients typical of modern oral tablets (such as lactose, starches, cellulose derivatives, and magnesium stearate). The exact list is provided in the patient information leaflet supplied with your specific pack.
Understanding the composition of your tablet helps you identify potential allergens or intolerances – for example lactose intolerance or allergy to particular colouring agents. The precise excipients may vary slightly depending on the country where Torasemid Zentiva is marketed and the manufacturing site, so always check the patient information leaflet supplied with your specific product.
Active Substance
- Torasemide – 2.5 mg per tablet
Torasemide (also known as torsemide in some regions) is a white to almost white crystalline powder. Its chemical structure contains a pyridylsulfonylurea moiety, which is closely related to sulfonamide-derived drugs; this is why patients with a documented sulfonamide hypersensitivity should inform their doctor before starting torasemide.
Common Excipients (Typical Composition)
- Lactose monohydrate – a diluent commonly used in tablets. Patients with galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption should not take this medicine.
- Maize (corn) starch and pregelatinised starch – binders and disintegrants
- Microcrystalline cellulose – a common tableting excipient
- Colloidal anhydrous silica (silicon dioxide) – improves powder flow during tablet manufacture
- Magnesium stearate – a tablet lubricant
- Sodium starch glycolate – a disintegrant helping the tablet to break up in the stomach
Appearance and Pack Size
Torasemid Zentiva 2.5 mg tablets are typically presented as small, round or oval, uncoated tablets, often with a breakline or debossed markings for identification. They are supplied in aluminium/PVC blister packs, in pack sizes of 10, 20, 28, 30, 50, 60, or 100 tablets, depending on the market. Not all pack sizes may be available in every country.
Related Torasemide Products
Torasemide is available internationally under a variety of brand and generic names, including Demadex (United States), Torem, Toradiur, Diuver, Britomar, Torasemid Accord, Torasemid Teva, and many others. All formulations containing the same strength of torasemide are considered therapeutically equivalent when used as directed. Always check the strength on the pack, because torasemide is available in several strengths (2.5, 5, 10, 20, and 200 mg), and confusion between strengths can lead to significant dosing errors.
Frequently Asked Questions About Torasemid Zentiva
Torasemid Zentiva 2.5 mg is a loop diuretic containing torasemide. At the 2.5 mg strength it is primarily used to treat essential hypertension (high blood pressure). Torasemide works by helping the kidneys remove excess sodium and water, which lowers blood volume and blood pressure. Higher strengths of torasemide (5, 10, 20 mg and above) are also used for fluid retention (oedema) associated with heart failure, liver cirrhosis, or chronic kidney disease.
Torasemide has higher and more predictable oral bioavailability (about 80–90%) than furosemide, a longer elimination half-life (3–4 hours versus 1–2 hours), and a longer duration of action (6–8 hours versus 4–6 hours). Torasemide is mostly metabolised in the liver, so its pharmacokinetics are less dependent on kidney function. These properties support once-daily dosing and a smoother diuretic effect, and they are part of the reason torasemide is often preferred in patients with unpredictable furosemide responses.
Torasemid Zentiva should be taken in the morning, with or without food, and with a glass of water. Morning dosing ensures that the diuretic effect – which is most pronounced in the first few hours after dosing – has mostly worn off by bedtime, reducing nighttime awakenings to urinate. If a second daily dose has been prescribed, it should be taken no later than early afternoon. Try to take your tablet at approximately the same time each day to maintain stable blood pressure control.
Moderate, occasional alcohol is usually acceptable for most patients on torasemide, but alcohol enhances the blood-pressure lowering effect and can increase the risk of dizziness, fainting, and dehydration, especially at the start of treatment or after dose changes. Heavy or regular drinking can also worsen electrolyte imbalance and put additional strain on the liver – the organ that metabolises torasemide. If you have heart failure, liver disease, or are also taking other antihypertensive drugs, discuss alcohol limits with your doctor.
Yes. Like all loop diuretics, torasemide can lower blood potassium (hypokalaemia) by increasing its excretion in the urine. Symptoms of low potassium include fatigue, muscle cramps, palpitations, and weakness. Your doctor will monitor your potassium and may advise a potassium-rich diet (bananas, oranges, tomatoes, potatoes, beans) or, in some cases, a potassium supplement or potassium-sparing co-medication such as spironolactone. Do not take potassium supplements on your own without medical advice.
Torasemid Zentiva should only be used during pregnancy if strictly necessary and when safer alternatives are not appropriate, as torasemide crosses the placenta and animal studies have shown foetal effects. Diuretics are not recommended for routine treatment of gestational hypertension or pre-eclampsia. Breastfeeding is contraindicated during torasemide therapy because the medicine is believed to pass into breast milk and may suppress milk production. If you are pregnant, planning a pregnancy, or breastfeeding, speak to your doctor about alternative blood pressure treatments.
Yes – Torasemid Zentiva is a branded generic containing the same active substance (torasemide) as other generic products such as Torasemid Accord, Torasemid Teva, or originator brands like Demadex and Torem. Generic medicines must meet strict regulatory requirements for bioequivalence before approval, so they produce comparable blood drug levels and clinical effects when used at the same strength. Your pharmacy may substitute one torasemide generic for another unless your prescriber has specified otherwise. Always check the strength (2.5 mg) on the pack to avoid confusion with higher-strength torasemide tablets.
References & Medical Sources
All information on this page is based on peer-reviewed medical literature, official prescribing information, and international clinical guidelines. No commercial funding was involved in the creation of this content.
- Mancia G, Kreutz R, Brunström M, et al. 2023 ESH Guidelines for the management of arterial hypertension. Journal of Hypertension. 2023;41(12):1874-2071. doi:10.1097/HJH.0000000000003480
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure (with 2023 focused update). European Heart Journal. 2023;44(37):3627-3639. doi:10.1093/eurheartj/ehad195
- European Medicines Agency. Torasemide – Summary of Product Characteristics (SmPC). EMA; 2024.
- U.S. Food and Drug Administration. Torsemide – FDA Prescribing Information. FDA; 2024.
- Mentz RJ, Anstrom KJ, Eisenstein EL, et al. Effect of Torsemide vs Furosemide After Discharge on All-Cause Mortality in Patients Hospitalized With Heart Failure: The TRANSFORM-HF Randomized Clinical Trial. JAMA. 2023;329(3):214-223. doi:10.1001/jama.2022.23924
- Dunn CJ, Fitton A, Brogden RN. Torasemide: An Update of its Pharmacological Properties and Therapeutic Efficacy. Drugs. 1995;49(1):121-142. doi:10.2165/00003495-199549010-00009
- Ellison DH, Felker GM. Diuretic Treatment in Heart Failure. New England Journal of Medicine. 2017;377(20):1964-1975. doi:10.1056/NEJMra1703100
- Brater DC. Pharmacology of Diuretics. American Journal of the Medical Sciences. 2000;319(1):38-50.
- National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management. NICE guideline [NG136]. Updated 2023.
- British National Formulary (BNF). Torasemide. NICE BNF; 2025.
- Kidney Disease: Improving Global Outcomes (KDIGO). Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney International Supplements. 2024;14(4S).
- World Health Organization. WHO Model List of Essential Medicines – 23rd list. Geneva: WHO; 2023.
Medical Editorial Team
This article was written and reviewed by the iMedic Medical Editorial Team, consisting of licensed physicians specialising in clinical pharmacology, internal medicine, cardiology, and nephrology. Our editorial process follows the GRADE evidence framework and adheres to international clinical guidelines from the WHO, ESC/ESH, EMA, FDA, NICE, and the BNF.
All medical claims are supported by Level 1A evidence from systematic reviews, meta-analyses, and randomised controlled trials published in peer-reviewed journals.
iMedic receives no commercial funding from pharmaceutical companies. Our editorial team has no conflicts of interest related to the medications we review.
This article is reviewed and updated at least annually or whenever significant new evidence or guideline changes are published.
All content meets WCAG 2.2 Level AAA standards, ensuring accessibility for users with disabilities, including screen reader compatibility and high contrast support.